Takeda to Initiate the Development of Plasma-Derived Therapy to Treat Corona Virus (COVID-19)

Takeda to Initiate the Development of Plasma-Derived Therapy to Treat Corona Virus (COVID-19)

Shots:

  • Takeda initiates the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), TAK-888 for the treatment of high-risk individuals with COVID-19 and evaluates its marketed and pipeline products as viable candidates for COVID-19
  • Takeda is currently working with multiple national health and regulatory agencies in the US, EU, and Asia to expedite the research of TAK-888
  • H-IG works by concentrating the pathogen-specific Ab from plasma collected from recovered patients/vaccinated donors in the future. Takeda will initially produce the therapy in a segregated area within its manufacturing facility in Georgia

Click here to­ read full press release/ article | Ref: Takeda | Image: StraitTimes